Adding trastuzumab to maintenance therapy for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests whether adding a targeted therapy (trastuzumab) to the usual maintenance drug (bevacizumab) helps keep ovarian cancer from coming back after first-line chemo. It is for people with certain genetic markers and who have completed initial treatment without the cancer growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer (confirmed by biopsy).
- You have finished your first round of chemotherapy (with bevacizumab) and your cancer has not progressed.
- You have a specific genetic test result (HRD) that meets the study's needs.
- You must be able to provide a tumor sample (fresh or archived) for central testing.
- You are in good daily condition (ECOG score 0–1) and expected to live at least 12 weeks.
- You do not have untreated brain metastases, active infections, or serious heart/lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs (trastuzumab rezetecan and bevacizumab) for women with ovarian cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer longer.
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This study tests whether adding a new pill (INCB123667) to the usual maintenance drug bevacizumab (Avastin) can keep ovarian cancer from coming back, compared to bevacizumab alone. It is for women who have finished their first chemo and are in remission or have stable disease.
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.